Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Vinpocetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.83 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.83 |
| ▸ | PDE1A | P54750 | 18/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.83 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.83 |
| ▸ | MAPT | P10636 | 1/20 | 0.83 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.83 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.83 |
| ▸ | DRD3 | P35462 | 1/20 | 0.83 |
| ▸ | HTR2B | P41595 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinpocetine SCHEMBL6246968 | 0.91 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL160952 | 0.91 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL10571708 | 0.91 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL20077503 | 0.91 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL7947532 | 0.91 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL20077534 | 0.91 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL50081 | 0.91 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL21098929 | 0.91 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL21370424 | 0.91 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL29366611 | 0.91 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0760240-B1 | Composition for stimulating the cerebral activity comprising vinpocetine citrate and a plant extract comprising xanthines | DECOX S L (ES) | 2005-10-12 | — | — | EP | claimed |
| US-6290994-B1 | Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity | DECOX, S.L. (ES) | 2001-09-18 | — | — | US | claimed |
| EP-0154756-B2 | Citrate of vinpocetine, and process for its preparation | COVEX SA (ES) | 1996-10-23 | — | — | EP | claimed |
| EP-0154756-B1 | CITRATE OF VINPOCETINE, AND PROCESS FOR ITS PREPARATION | COVEX (S.A.) (ES) | 1989-08-16 | — | — | EP | claimed |
| US-4749707-A | VASODILATION; CEREBRAL OXYGENATION IN ELDERLY | COVEX, S.A. (ES) | 1988-06-07 | — | — | US | claimed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| WO-2016118787-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-9308181-B2 | Topical formulations, systems and methods | NUVO RESEARCH INC. (CA) | 2016-04-12 | — | — | US | disclosed |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | LUITPOLD PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| US-6290994-B1 | Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity | DECOX, S.L. (ES) | 2001-09-18 | — | — | US | disclosed |
| US-6290994-B1 | Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity | DECOX, S.L. (ES) | 2001-09-18 | — | — | US | disclosed |
| US-6290994-B1 | Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity | DECOX, S.L. (ES) | 2001-09-18 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0760240-A1 | NOVEL COMPOSITION STIMULATING THE CEREBRAL ACTIVITY AND BASED ON ALCALOIDS HAVING AN EBURNAMENINE NUCLEUS, AND PREPARATION METHODS | Decox, S.L. (ES) | 1997-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | FABP7, FADS2, ALOX5 | MEN1 3392/4885ADORA1 1374/4885PDE1A 878/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | MEN1 3479/4885ADORA1 709/4885PDE1A 1859/4885 |
| US-20170216314-A1 | TOPICAL FORMULATIONS | SMURF1, SGMS1, SPTLC1 | MEN1 4709/4885ADORA1 3383/4885PDE1A 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.